Science Immunology

Supplementary Materials

The PDF file includes:

  • Materials and Methods
  • Table S1. List of antibodies used for flow cytometry and immunohistochemistry examination.
  • Table S2. Pharmacokinetic profiles of the antibody nanoparticles.
  • Fig. S1. Synthetic route for MMP-2–liable PEG-PLGLAG-dEGCG.
  • Fig. S2. Electrospray ionization (ESI) mass spectrum of the dimer of EGCG (dEGCG).
  • Fig. S3. Matrix-assisted laser desorption/ionization–time-of-flight (MALDI-TOF) mass spectra of EGCG conjugates.
  • Fig. S4. HPLC examination of MMP-2–mediated degradation of the PLGLAG spacer.
  • Fig. S5. MALDI-TOF mass spectra of MMP-2–insensitive PEGylated EGCG.
  • Fig. S6. Characterization of S-αPDL1/ICG@NP assembly process.
  • Fig. S7. Representative TEM image of the S-αPDL1/ICG@NP.
  • Fig. S8. Serum stability of S-αPDL1/ICG@NP.
  • Fig. S9. PDL1 binding affinity of αPDL1 in S-αPDL1/ICG@NP post PDT.
  • Fig. S10. ESR spectroscopic examination of S-αPDL1/ICG@NP–induced ROS.
  • Fig. S11. S-αPDL1/ICG@NP induced ROS generation and phototoxicity in vitro.
  • Fig. S12. Flow cytometric examination of PDL1 expression in different cell lines.
  • Fig. S13. Intracellular uptake property of S-αPDL1/ICG@NP.
  • Fig. S14. Pharmacokinetic profiles of nanoparticles in vivo.
  • Fig. S15. Fluorescence imaging of 4T1 tumors at desired time after different treatments.
  • Fig. S16. Immunohistochemical examination of MMP-2 expression.
  • Fig. S17. Quantification of αPDL1 distribution in major organs.
  • Fig. S18. Normalized tumoral infiltration of CD3+ and CD4+ T cells in control and treated groups.
  • Fig. S19. The tumor growth plots of 4T1 tumor–bearing mice in control and treated groups.
  • Fig. S20. Body weight change recorded during the experimental period.
  • Fig. S21. H&E staining of the normal organs examined at the end of the antitumor study.
  • Fig. S22. TUNEL analysis of S-αPDL1/ICG@NP–mediated antitumor effects.
  • Fig. S23. H&E staining of the lung sections at the end of the antitumor study.
  • Fig. S24. Relative growth curves of B16-F10 tumors after various treatments.
  • Fig. S25. Survival curves of B16-F10 tumors in control and treated groups.

Download PDF

Other Supplementary Material for this manuscript includes the following:

  • Data S1. Raw data for Figs. 2 to 6 (Excel).
  • Data S2. Raw data for figs. S6 to S24 (Excel).

Files in this Data Supplement:

More From Science Immunology